GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

>rFVIIa is expensive as hell<

No kidding. Care to conjecture what they might ask for it?
Between that error bar and that of the price elasticity of
demand it seems like estimating its potential market would
be pretty tough, even for you. Would they price it purely
on revenue maximization vs the clear indications, or cheaper
to try to expand its scope of application?